



OPEN ACCESS

APPROVED BY

Michael Heinrich,
University College London,
United Kingdom

*CORRESPONDENCE

Frontiers Editorial Office,
✉ research.integrity@frontiersin.org

RECEIVED 22 September 2023

ACCEPTED 22 September 2023

PUBLISHED 06 October 2023

CITATION

Frontiers Editorial Office (2023),
Retraction: Icariin ameliorates palmitate-
induced insulin resistance through
reducing thioredoxin-interacting protein
(TXNIP) and suppressing ER stress
in C2C12 myotubes.
Front. Pharmacol. 14:1299165.
doi: 10.3389/fphar.2023.1299165

COPYRIGHT

© 2023 Frontiers Editorial Office. This is
an open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Retraction: Icariin ameliorates palmitate-induced insulin resistance through reducing thioredoxin-interacting protein (TXNIP) and suppressing ER stress in C2C12 myotubes

Frontiers Editorial Office*

A Retraction of the Original Research Article

[Icariin ameliorates palmitate-induced insulin resistance through reducing thioredoxin-interacting protein \(TXNIP\) and suppressing ER stress in C2C12 myotubes](#)

by Li M, Zhang Y, Cao Y, Zhang D, Liu L, Guo Y and Wang C (2018). *Front. Pharmacol.* 9:1180. doi: 10.3389/fphar.2018.01180

The journal retracts the 2018 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures. Image duplication concerns were identified in **Figures 1C, 2B, 6C, E, and 7E**. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.

This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors have not responded to correspondence regarding this retraction.